Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.
Bansi argues that rare disease pharmacy is a fundamentally different model built around precision, speed, and hyper-personalized care. He suggests how manufacturers and stakeholders must rethink their assumptions to effectively support the unique demands of rare disease patient journeys.
